Novartis: positive opinion from EMA for Cosentyx
(CercleFinance.com) - Today Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx (secukinumab) for extended use in childhood arthritis.
The treatment is used alone, or in combination with methotrexate, in the categories of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPA) in patients aged 6 years and older whose disease has not responded adequately to or is intolerant of conventional therapy.
JIA is the most common childhood rheumatic disease, affecting millions of children worldwide. Unfortunately, due to the limitations of current or available treatment options, some patients continue to experience symptoms, which impacts their lives. If approved in Europe, Cosentyx could provide a much-needed additional effective treatment for underserved ERA and JPsA patient populations, the Center for Pediatric Rheumatology in Hamburg, Germany said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The treatment is used alone, or in combination with methotrexate, in the categories of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPA) in patients aged 6 years and older whose disease has not responded adequately to or is intolerant of conventional therapy.
JIA is the most common childhood rheumatic disease, affecting millions of children worldwide. Unfortunately, due to the limitations of current or available treatment options, some patients continue to experience symptoms, which impacts their lives. If approved in Europe, Cosentyx could provide a much-needed additional effective treatment for underserved ERA and JPsA patient populations, the Center for Pediatric Rheumatology in Hamburg, Germany said.
Copyright (c) 2022 CercleFinance.com. All rights reserved.